A Director at Antares Pharma is Exercising Options

By Carrie Williams

Today, a Director at Antares Pharma, Leonard Jacob, exercised options of Antares Pharma for $27.55K. The options were close to expired and Leonard Jacob retained stocks.

Following this transaction Leonard Jacob’s holding in the company was increased by 15.62% to a total of $527.8K. Following Leonard Jacob’s last ATRS Buy transaction on March 21, 2016, the stock climbed by 1.4%.

Based on Antares Pharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $14.04 million and GAAP net loss of $3.71 million. In comparison, last year the company earned revenue of $12.01 million and had a GAAP net loss of $4.74 million. The company has a one-year high of $4.09 and a one-year low of $1.58. Currently, Antares Pharma has an average volume of 1.51M.

Starting in August 2016, ATRS received 20 Buy ratings in a row. Seven different firms, including Jefferies and Ladenburg, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a pharmaceutical company. The company focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its activities include the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.